These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

232 related articles for article (PubMed ID: 20616092)

  • 1. HIV, transmitted drug resistance, and the paradox of preexposure prophylaxis.
    Supervie V; García-Lerma JG; Heneine W; Blower S
    Proc Natl Acad Sci U S A; 2010 Jul; 107(27):12381-6. PubMed ID: 20616092
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long-Acting Rilpivirine (RPV) Preexposure Prophylaxis Does Not Inhibit Vaginal Transmission of RPV-Resistant HIV-1 or Select for High-Frequency Drug Resistance in Humanized Mice.
    Melody K; Roy CN; Kline C; Cottrell ML; Evans D; Shutt K; Pennings PS; Keele BF; Bility M; Kashuba ADM; Ambrose Z
    J Virol; 2020 Mar; 94(8):. PubMed ID: 31969438
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Preexposure prophylaxis will have a limited impact on HIV-1 drug resistance in sub-Saharan Africa: a comparison of mathematical models.
    van de Vijver DA; Nichols BE; Abbas UL; Boucher CA; Cambiano V; Eaton JW; Glaubius R; Lythgoe K; Mellors J; Phillips A; Sigaloff KC; Hallett TB
    AIDS; 2013 Nov; 27(18):2943-51. PubMed ID: 23939237
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Preexposure Prophylaxis for HIV Infection Integrated With Municipal- and Community-Based Sexual Health Services.
    Liu AY; Cohen SE; Vittinghoff E; Anderson PL; Doblecki-Lewis S; Bacon O; Chege W; Postle BS; Matheson T; Amico KR; Liegler T; Rawlings MK; Trainor N; Blue RW; Estrada Y; Coleman ME; Cardenas G; Feaster DJ; Grant R; Philip SS; Elion R; Buchbinder S; Kolber MA
    JAMA Intern Med; 2016 Jan; 176(1):75-84. PubMed ID: 26571482
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Acute HIV at the Time of Initiation of Pre-exposure or Post-exposure Prophylaxis: Impact on Drug Resistance and Clinical Outcomes.
    Johnson KA; Chen MJ; Kohn R; Sachdev D; Bacon O; Lee S; Cohen SE
    J Acquir Immune Defic Syndr; 2021 Jun; 87(2):818-825. PubMed ID: 33512849
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evolutionary dynamics of complex networks of HIV drug-resistant strains: the case of San Francisco.
    Smith RJ; Okano JT; Kahn JS; Bodine EN; Blower S
    Science; 2010 Feb; 327(5966):697-701. PubMed ID: 20075214
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The cost-effectiveness of oral HIV pre-exposure prophylaxis and early antiretroviral therapy in the presence of drug resistance among men who have sex with men in San Francisco.
    Shen M; Xiao Y; Rong L; Meyers LA; Bellan SE
    BMC Med; 2018 Apr; 16(1):58. PubMed ID: 29688862
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Population Impact and Efficiency of Improvements to HIV PrEP Under Conditions of High ART Coverage Among San Francisco Men Who Have Sex With Men.
    Le Guillou A; Buchbinder S; Scott H; Liu A; Havlir D; Scheer S; Jenness SM
    J Acquir Immune Defic Syndr; 2021 Dec; 88(4):340-347. PubMed ID: 34354011
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Individual HIV Risk versus Population Impact of Risk Compensation after HIV Preexposure Prophylaxis Initiation among Men Who Have Sex with Men.
    Jenness SM; Sharma A; Goodreau SM; Rosenberg ES; Weiss KM; Hoover KW; Smith DK; Sullivan P
    PLoS One; 2017; 12(1):e0169484. PubMed ID: 28060881
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Analytic review of modeling studies of ARV Based PrEP interventions reveals strong influence of drug-resistance assumptions on the population-level effectiveness.
    Dimitrov D; Boily MC; Brown ER; Hallett TB
    PLoS One; 2013; 8(11):e80927. PubMed ID: 24282559
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Should we fear resistance from tenofovir/emtricitabine preexposure prophylaxis?
    Parikh UM; Mellors JW
    Curr Opin HIV AIDS; 2016 Jan; 11(1):49-55. PubMed ID: 26633640
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Are current guidelines adapted for patient eligibility to PrEP? A case report.
    Van Obberghen EK; Viard D; Lafeuillade A; Civiletti A; Rocher F; Drici MD
    BMC Infect Dis; 2019 Jul; 19(1):601. PubMed ID: 31291899
    [TBL] [Abstract][Full Text] [Related]  

  • 13. High interest in preexposure prophylaxis among men who have sex with men at risk for HIV infection: baseline data from the US PrEP demonstration project.
    Cohen SE; Vittinghoff E; Bacon O; Doblecki-Lewis S; Postle BS; Feaster DJ; Matheson T; Trainor N; Blue RW; Estrada Y; Coleman ME; Elion R; Castro JG; Chege W; Philip SS; Buchbinder S; Kolber MA; Liu AY
    J Acquir Immune Defic Syndr; 2015 Apr; 68(4):439-48. PubMed ID: 25501614
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A tale of two futures: HIV and antiretroviral therapy in San Francisco.
    Blower SM; Gershengorn HB; Grant RM
    Science; 2000 Jan; 287(5453):650-4. PubMed ID: 10649998
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Introducing pre-exposure prophylaxis to prevent HIV acquisition among men who have sex with men in Sweden: insights from a mathematical pair formation model.
    Hansson D; Strömdahl S; Leung KY; Britton T
    BMJ Open; 2020 Feb; 10(2):e033852. PubMed ID: 32029492
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Systemic preexposure prophylaxis for HIV: translating clinical data to clinical practice.
    Li J; Dufrene SL; Okulicz JF
    Ann Pharmacother; 2014 Apr; 48(4):507-18. PubMed ID: 24473492
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antiretroviral therapy and pre-exposure prophylaxis: combined impact on HIV transmission and drug resistance in South Africa.
    Abbas UL; Glaubius R; Mubayi A; Hood G; Mellors JW
    J Infect Dis; 2013 Jul; 208(2):224-34. PubMed ID: 23570850
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Missed opportunities to prevent HIV infections among pre-exposure prophylaxis users: a population-based mixed methods study, San Francisco, United States.
    Spinelli MA; Laborde N; Kinley P; Whitacre R; Scott HM; Walker N; Liu AY; Gandhi M; Buchbinder SP
    J Int AIDS Soc; 2020 Apr; 23(4):e25472. PubMed ID: 32294338
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prevalence and characteristics of users of pre-exposure prophylaxis (PrEP) among men who have sex with men, San Francisco, 2014 in a cross-sectional survey: implications for disparities.
    Snowden JM; Chen YH; McFarland W; Raymond HF
    Sex Transm Infect; 2017 Feb; 93(1):52-55. PubMed ID: 27356041
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Does HIV Pre-Exposure Prophylaxis Modify the Effect of Partnership Characteristics on Condom Use? A Cross-Sectional Study of Sexual Partnerships Among Men Who Have Sex with Men in San Francisco, California.
    Prescott MR; Hern J; Petersen M; Santos GM
    AIDS Patient Care STDS; 2019 Apr; 33(4):167-174. PubMed ID: 30932698
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.